1241894-37-0

Basic information

• Product Name: (5-bromo-2-nitrophenyl)methanol
• Synonyms: (5-bromo-2-nitrophenyl)methanol;5-Bromo-2-nitrobenzylalcohol
• CAS NO: 1241894-37-0
• Molecular Formula: C₇H₆BrNO₃
• Molecular Weight: 232.03144
• Mol File: 1241894-37-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (5-bromo-2-nitrophenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (5-bromo-2-nitrophenyl)methanol(1241894-37-0)
• EPA Substance Registry System: (5-bromo-2-nitrophenyl)methanol(1241894-37-0)

Safety Data

• Hazardous Substances Data: 1241894-37-0(Hazardous Substances Data)

Usage

General Description

(5-bromo-2-nitrophenyl)methanol is a chemical compound with the molecular formula C7H6BrNO4. It is a yellow crystalline powder that is commonly used as a reagent in organic synthesis, particularly in the production of pharmaceuticals, agrochemicals, and dyes. (5-bromo-2-nitrophenyl)methanol is known for its ability to undergo various chemical reactions, including substitution, reduction, and oxidation, making it valuable in the development of new compounds and materials. It is also used as a building block in the synthesis of complex organic molecules and is known for its potential applications in the field of medicinal chemistry and drug discovery. The compound is considered to be relatively stable under normal conditions, making it suitable for a wide range of research and industrial processes.

Upstream product

• 883554-93-6 methyl 5-bromo-2-nitro-3-methoxybenzoate 
• 585-76-2 m-bromobenzoic acid 
• 3132-99-8 m-bromobenzoic aldehyde 
• 20357-20-4 5-bromo-2-nitrobenzaldehyde 
• 6950-43-2 5-bromo-2-nitrobenzoic acid 

Downstream Products

• 1241894-39-2 5-bromo-2-nitrobenzyl ethanoate 
• 1241894-28-9 5-[bis(4'-tert-butylbiphenyl-4-yl)amino]-2-nitrobenzyl ethanoate 
• 1379595-72-8 C₃₉H₄₀N₂O₃ 

Relevant articles and documents

Caged glutamates with π-extended 1,2-dihydronaphthalene chromophore: Design, synthesis, two-photon absorption property, and photochemical reactivity

Caging and photochemical uncaging of the excitatory neurotransmitter l-glutamate (glu) offers a potentially valuable tool for understanding the mechanisms of neuronal processes. Designing water-soluble caged glutamates with the appropriate two-photon absorption property is an attractive strategy to achieve this. This paper describes the design, synthesis, and photochemical reactivity of caged glutamates with π-extended 1,2-dihydronaphthalene structures, which possess a two-photon cross-section of ～120 GM and an excellent buffer solubility (up to 115 mM). High yields up to 99% glutamate were observed in the photolysis of two caged glutamates. Suzuki-Miyaura cross-coupling and Buchwald-Hartwig amination were used as the key reactions to synthesize the caged compounds.

Palladium-Catalyzed Regioselective Syn-Chloropalladation-Olefin Insertion-Oxidative Chlorination Cascade: Synthesis of Dichlorinated Tetrahydroquinolines

A palladium catalyzed cascade process involving syn-chloropalladation, intramolecular olefin insertion, and oxidative C-Cl bond formation reactions was demonstrated for the synthesis of dichlorinated tetrahydroquinolines in high yields (up to 93%). The N-propargyl arylamines having a tethered α,β-unsaturated carbonyl moiety underwent a regioselective syn-chloropalladation followed by a Heck-type reaction to deliver the tetrahydroquinoline scaffold. The rare insertion of the second chlorine atom was rationalized comprising a PdII/IV catalytic cycle and oxidative cleavage of the C-PdII bond.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R", Q, W, X, Y, Z, n1, n2and '--" are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also disclosed.

Co-delivery system of photo-responsive chemotherapeutic drug and preparation method thereof

The invention discloses a co-delivery system of a photo-responsive chemotherapeutic drug and a preparation method thereof. A prodrug is prepared through covalent linkage of a double branched type photosensitive carrier with o-nitrobenzyl as a structural u